Ignite Creation Date:
2024-05-05 @ 5:29 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00461357
Status:
UNKNOWN
Last Update Posted:
2007-04-18
First Post:
2007-04-17
Brief Title:
Sirolimus Based Immunosuppression for Patients Undergoing Kidney Transplantation in the Eurotransplant Senior Program
Sponsor:
Medical University of Vienna
Organization:
Medical University of Vienna
Study Overview
Official Title:
Outcome After Renal Transplantation of a Randomized Prospective Trial in the Eurotransplant Senior Program
Status:
UNKNOWN
Status Verified Date:
2007-04
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ESP
Brief Summary:
The Eurotransplant Senior Program ESP started in 1999 with local allocation of kidneys from deceased donors elder than 65 years to recipients elder than 65 years The requirements for immunosuppression in this group of patients are high due to the large amount of comorbidities
This prospective randomized trial compared the standard immunosuppressive protocol based on cyclosporine A CyA used at our center within the ESP to a calcineurin inhibitor-free protocol based on sirolimus SRL
The aim of this study is to investigate the effect of a CNI-free therapy on the function of elderly kidneys 6 months post transplantation measured by GFR
This prospective randomized trial compared the standard immunosuppressive protocol based on cyclosporine A CyA used at our center within the ESP to a calcineurin inhibitor-free protocol based on sirolimus SRL
The aim of this study is to investigate the effect of a CNI-free therapy on the function of elderly kidneys 6 months post transplantation measured by GFR
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None